Tags

Type your tag names separated by a space and hit enter

Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use.
Lancet 1983; 2(8356):926-30Lct

Abstract

A case-control study of 314 breast cancer patients aged less than 37 at diagnosis and 314 individually matched controls was done to assess the influence of oral-contraceptive (OC) use on the risk of the disease. Long-term use before age 25 of combination-type OCs with a "high" content of the progestogen component was associated with increased risk of breast cancer: the relative risk was approximately 4 after 5 years of such use, and 9 cases and no controls had used such combination-type OCs for more than 6 years before age 25. Use of combination-type OCs with a "low" progestogen component appears to increase breast-cancer risk little or not at all.

Links

  • Publisher Full Text

    • Authors

    Pike MC
    No affiliation info available
    Henderson BE
    No affiliation info available
    Krailo MD
    No affiliation info available
    Duke A
    No affiliation info available
    Roy S
    No affiliation info available

    MeSH

    AdultAge FactorsBreastBreast NeoplasmsContraceptives, OralDrug CombinationsEndometriumFemaleHumansMitosisNorethindroneNorethindrone AcetateOvaryPregnancyRiskTime Factors

    Pub Type(s)

    Comparative Study
    Journal Article
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    6138501

    Citation

    Pike, M C., et al. "Breast Cancer in Young Women and Use of Oral Contraceptives: Possible Modifying Effect of Formulation and Age at Use." Lancet (London, England), vol. 2, no. 8356, 1983, pp. 926-30.
    Pike MC, Henderson BE, Krailo MD, et al. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet. 1983;2(8356):926-30.
    Pike, M. C., Henderson, B. E., Krailo, M. D., Duke, A., & Roy, S. (1983). Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet (London, England), 2(8356), pp. 926-30.
    Pike MC, et al. Breast Cancer in Young Women and Use of Oral Contraceptives: Possible Modifying Effect of Formulation and Age at Use. Lancet. 1983 Oct 22;2(8356):926-30. PubMed PMID: 6138501.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. AU - Pike,M C, AU - Henderson,B E, AU - Krailo,M D, AU - Duke,A, AU - Roy,S, PY - 1983/10/22/pubmed PY - 1983/10/22/medline PY - 1983/10/22/entrez KW - Age Factors KW - Biology KW - Birth Order KW - Breast Cancer KW - Cancer KW - Contraception KW - Contraceptive Agents KW - Contraceptive Agents, Female KW - Contraceptive Methods--side effects KW - Control Groups KW - Demographic Factors KW - Diseases KW - Endocrine System KW - Estrogens KW - Family And Household KW - Family Characteristics KW - Family Planning KW - Family Relationships KW - Fertility KW - Fertility Measurements KW - First Birth KW - High Risk Women KW - Hormones KW - Menarche KW - Menopause KW - Neoplasms KW - Oral Contraceptives, Combined KW - Oral Contraceptives--side effects KW - Physiology KW - Population KW - Population Characteristics KW - Population Dynamics KW - Pregnancy History KW - Progestational Hormones KW - Progesterone KW - Reproduction KW - Reproductive Control Agents KW - Research Methodology KW - Time Factors SP - 926 EP - 30 JF - Lancet (London, England) JO - Lancet VL - 2 IS - 8356 N2 - A case-control study of 314 breast cancer patients aged less than 37 at diagnosis and 314 individually matched controls was done to assess the influence of oral-contraceptive (OC) use on the risk of the disease. Long-term use before age 25 of combination-type OCs with a "high" content of the progestogen component was associated with increased risk of breast cancer: the relative risk was approximately 4 after 5 years of such use, and 9 cases and no controls had used such combination-type OCs for more than 6 years before age 25. Use of combination-type OCs with a "low" progestogen component appears to increase breast-cancer risk little or not at all. SN - 0140-6736 UR - https://www.unboundmedicine.com/medline/citation/6138501/Breast_cancer_in_young_women_and_use_of_oral_contraceptives:_possible_modifying_effect_of_formulation_and_age_at_use_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(83)90450-6 DB - PRIME DP - Unbound Medicine ER -